Impact of epigenetic dietary components on cancer through histone modifications

Current Medicinal Chemistry

Volumn 22, Issue 17, 2015, Pages 2051-2064

  Gao, Yifeng ^a   Tollefsbol, Trygve O ^a,b,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cancer; Dietary components; Epigenetics; Gene expression; Histone modifications; Phytochemicals

Indexed keywords

3,3' DIINDOLYLMETHANE; BENZYL ISOTHIOCYANATE; CURCUMIN; DIALLYL DISULFIDE; EPIGALLOCATECHIN GALLATE; GARCINOL; GENISTEIN; HISTONE; ISOTHIOCYANIC ACID DERIVATIVE; PHENYLHEXYL ISOTHIOCYANATE; PROCYANIDIN; PROCYANIDIN B3; QUERCETIN; RESVERATROL; SELENIUM; SULFORAPHANE; UNCLASSIFIED DRUG;

ARTICLE; EPIGENETICS; GENETIC ASSOCIATION; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NUTRIENT; ANIMAL; DIET; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASM;

ANIMALS; DIET; EPIGENESIS, GENETIC; HISTONES; HUMANS; NEOPLASMS;

EID: 84931274692     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150420102641     Document Type: Article

References (194)

1. Bhasin, M.; Reinherz, E. L.; Reche, P. A. Recognition and classification of histones using support vector machine. J. Comput. Biol., 2006, 13(1), 102-112.
2. Luger, K.; Mader, A. W.; Richmond, R. K.; Sargent, D. F.; Richmond, T. J. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature, 1997, 389(6648), 251-260.
3. Davis, C. D.; Ross, S. A. Dietary components impact histone modifications and cancer risk. Nutr. Rev., 2007, 65(2), 88-94.
4. Wagner, J. M.; Hackanson, B.; Lubbert, M.; Jung, M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin. Epigenetics, 2010, 1(3-4), 117-136.
5. Kouzarides, T. Chromatin modifications and their function. Cell, 2007, 128(4), 693-705.
6. Strahl, B. D.; Allis, C. D. The language of covalent histone modifications. Nature, 2000, 403(6765), 41-45.
7. Jenuwein, T.; Allis, C. D. Translating the histone code. Science, 2001, 293(5532), 1074-1080.
8. Chen, Z.; Wang, L.; Wang, Q.; Li, W. Histone modifications and chromatin organization in prostate cancer. Epigenomics, 2010, 2(4), 551-560.
9. Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature, 1997, 389(6649), 349-352.
10. Zhang, K.; Dent, S. Y. Histone modifying enzymes and cancer: going beyond histones. J. Cell. Biochem., 2005, 96(6), 1137-1148.
11. Lee, K. K.; Workman, J. L. Histone acetyltransferase complexes: one size doesn't fit all. Nat. Rev. Mol. Cell. Biol., 2007, 8(4), 284-295.
12. Yuan, H.; Marmorstein, R. Histone acetyltransferases: Rising ancient counterparts to protein kinases. Biopolymers, 2013, 99(2), 98-111.
13. Roth, S. Y.; Denu, J. M.; Allis, C. D. Histone acetyltransferases. Annu. Rev. Biochem., 2001, 70, 81-120.
14. Sterner, D. E.; Berger, S. L. Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev., 2000, 64(2), 435-459.
15. Ogryzko, V. V. Mammalian histone acetyltransferases and their complexes. Cell. Mol. Life Sci., 2001, 58(5-6), 683-692.
16. Doi, M.; Hirayama, J.; Sassone-Corsi, P. Circadian regulator CLOCK is a histone acetyltransferase. Cell, 2006, 125(3), 497-508.
17. Choudhary, C.; Kumar, C.; Gnad, F.; Nielsen, M. L.; Rehman, M.; Walther, T. C.; Olsen, J. V.; Mann, M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science, 2009, 325(5942), 834-840.
18. Dokmanovic, M.; Clarke, C.; Marks, P. A. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res., 2007, 5 (10), 981-989.
19. Yoo, C. B.; Jones, P. A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov., 2006, 5(1), 37-50.
20. Verdin, E.; Dequiedt, F.; Fischle, W.; Frye, R.; Marshall, B.; North, B. Measurement of mammalian histone deacetylase activity. Methods Enzymol., 2004, 377, 180-196.
21. Verdin, E.; Dequiedt, F.; Kasler, H. G. Class II histone deacetylases: versatile regulators. Trends Genet., 2003, 19(5), 286-93.
22. Sauve, A. A.; Wolberger, C.; Schramm, V. L.; Boeke, J. D. The biochemistry of sirtuins. Annu. Rev. Biochem., 2006, 75, 435-465.
23. Hartley, J. L.; Temple, G. F.; Brasch, M. A. DNA cloning using in vitro site-specific recombination. Genome Res., 2000, 10(11), 1788-1795.
24. Trapp, J.; Jung, M. The role of NAD+ dependent histone deacetylases (sirtuins) in ageing. Curr. Drug Targets, 2006, 7(11), 1553-1560.
25. Hrabeta, J.; Stiborova, M.; Adam, V.; Kizek, R.; Eckschlager, T. Histone deacetylase inhibitors in cancer therapy. A review. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 2014, 158(2), 161-169.
26. Marks, P. A.; Xu, W. S. Histone deacetylase inhibitors: Potential in cancer therapy. J. Cell. Biochem., 2009, 107(4), 600-8.
27. Wood, A.; Shilatifard, A. Posttranslational modifications of histones by methylation. Adv. Protein Chem., 2004, 67, 201-222.
28. Sawan, C.; Herceg, Z. Histone modifications and cancer. Adv. Genet., 2010, 70, 57-85.
29. Feng, Q.; Wang, H.; Ng, H. H.; Erdjument-Bromage, H.; Tempst, P.; Struhl, K.; Zhang, Y. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr. Biol., 2002, 12(12), 1052-1058.
30. Ng, H. H.; Feng, Q.; Wang, H.; Erdjument-Bromage, H.; Tempst, P.; Zhang, Y.; Struhl, K. Lysine methylation within the globular domain of histone H3 by Dot1 is important for telomeric silencing and Sir protein association. Genes Dev., 2002, 16(12), 1518-1527.
31. Branscombe, T. L.; Frankel, A.; Lee, J. H.; Cook, J. R.; Yang, Z.; Pestka, S.; Clarke, S. PRMT5 (Janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in proteins. J. Biol. Chem., 2001, 276(35), 32971-32976.
32. Chen, D.; Ma, H.; Hong, H.; Koh, S. S.; Huang, S. M.; Schurter, B. T.; Aswad, D. W.; Stallcup, M. R. Regulation of transcription by a protein methyltransferase. Science, 1999, 284(5423), 2174-7.
33. Gary, J. D.; Lin, W. J.; Yang, M. C.; Herschman, H. R.; Clarke, S. The predominant protein-arginine methyltransferase from Saccharomyces cerevisiae. J. Biol. Chem., 1996, 271(21), 12585-12594.
34. McBride, A. E.; Weiss, V. H.; Kim, H. K.; Hogle, J. M.; Silver, P. A. Analysis of the yeast arginine methyltransferase Hmt1p/Rmt1p and its in vivo function. Cofactor binding and substrate interactions. J. Biol. Chem., 2000, 275(5), 3128-3136.
35. Pal, S.; Sif, S. Interplay between chromatin remodelers and protein arginine methyltransferases. J. Cell. Physiol., 2007, 213(2), 306-315.
36. Choudhuri, S.; Cui, Y.; Klaassen, C. D. Molecular targets of epigenetic regulation and effectors of environmental influences. Toxicol. Appl. Pharmacol., 2010, 245(3), 378-393.
37. Dillon, S. C.; Zhang, X.; Trievel, R. C.; Cheng, X. The SETdomain protein superfamily: protein lysine methyltransferases. Genome Biol., 2005, 6(8), 227.
38. Weiss, V. H.; McBride, A. E.; Soriano, M. A.; Filman, D. J.; Silver, P. A.; Hogle, J. M. The structure and oligomerization of the yeast arginine methyltransferase, Hmt1. Nat. Struct. Biol., 2000, 7(12), 1165-1171.
39. Zhang, X.; Zhou, L.; Cheng, X. Crystal structure of the conserved core of protein arginine methyltransferase PRMT3. EMBO J., 2000, 19(14), 3509-3519.
40. Trievel, R. C.; Beach, B. M.; Dirk, L. M.; Houtz, R. L.; Hurley, J. H. Structure and catalytic mechanism of a SET domain protein methyltransferase. Cell, 2002, 111(1), 91-103.
41. Klose, R. J.; Zhang, Y. Regulation of histone methylation by demethylimination and demethylation. Nat. Rev. Mol. Cell Biol., 2007, 8(4), 307-318.
42. Mosammaparast, N.; Shi, Y. Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Annu. Rev. Biochem., 2010, 79, 155-179.
43. Tochio, N.; Umehara, T.; Koshiba, S.; Inoue, M.; Yabuki, T.; Aoki, M.; Seki, E.; Watanabe, S.; Tomo, Y.; Hanada, M.; Ikari, M.; Sato, M.; Terada, T.; Nagase, T.; Ohara, O.; Shirouzu, M.; Tanaka, A.; Kigawa, T.; Yokoyama, S. Solution structure of the SWIRM domain of human histone demethylase LSD1. Structure, 2006, 14(3), 457-468.
44. Acharya, M. R.; Sparreboom, A.; Venitz, J.; Figg, W. D. Rational development of histone deacetylase inhibitors as anticancer agents: A review. Mol. Pharmacol., 2005, 68(4), 917-932.
45. Kim, D. H.; Kim, M.; Kwon, H. J. Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J. Biochem. Mol. Biol., 2003, 36(1), 110-119.
46. Kikuno, N.; Shiina, H.; Urakami, S.; Kawamoto, K.; Hirata, H.; Tanaka, Y.; Majid, S.; Igawa, M.; Dahiya, R. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int. J. Cancer, 2008, 123(3), 552-560.
47. Majid, S.; Kikuno, N.; Nelles, J.; Noonan, E.; Tanaka, Y.; Kawamoto, K.; Hirata, H.; Li, L. C.; Zhao, H.; Okino, S. T.; Place, R. F.; Pookot, D.; Dahiya, R. Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res., 2008, 68(8), 2736-44.
48. Dalvai, M.; Bystricky, K. The role of histone modifications and variants in regulating gene expression in breast cancer. J. Mammary Gland Biol. Neoplasia, 2010, 15(1), 19-33.
49. Ganesan, A.; Nolan, L.; Crabb, S. J.; Packham, G. Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery. Curr. Cancer Drug Targets, 2009, 9(8), 963-981.
50. McKitrick, T. R.; De Tomaso, A. W. Molecular mechanisms of allorecognition in a basal chordate. Semin. Immunol., 2010, 22(1), 34-38.
51. Sharma, S.; Kelly, T. K.; Jones, P. A. Epigenetics in cancer. Carcinogenesis, 2010, 31(1), 27-36.
52. Mottet, D.; Castronovo, V. Histone deacetylases: target enzymes for cancer therapy. Clin. Exp. Metastasis, 2008, 25(2), 183-189.
53. Myzak, M. C.; Dashwood, R. H. Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide, and sulforaphane. Curr. Drug Targets, 2006, 7(4), 443-452.
54. Jones, P. A.; Baylin, S. B. The epigenomics of cancer. Cell, 2007, 128(4), 683-692.
55. Kortenhorst, M. S.; Carducci, M. A.; Shabbeer, S. Acetylation and histone deacetylase inhibitors in cancer. Cell. Oncol., 2006, 28(5-6), 191-222.
56. Fraga, M. F.; Ballestar, E.; Villar-Garea, A.; Boix-Chornet, M.; Espada, J.; Schotta, G.; Bonaldi, T.; Haydon, C.; Ropero, S.; Petrie, K.; Iyer, N. G.; Perez-Rosado, A.; Calvo, E.; Lopez, J. A.; Cano, A.; Calasanz, M. J.; Colomer, D.; Piris, M. A.; Ahn, N.; Imhof, A.; Caldas, C.; Jenuwein, T.; Esteller, M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet., 2005, 37(4), 391-400.
57. Gibbons, R. J. Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum. Mol. Genet., 2005, 14 Spec No 1, R85-92.
58. Mork, C. N.; Faller, D. V.; Spanjaard, R. A. A mechanistic approach to anticancer therapy: targeting the cell cycle with histone deacetylase inhibitors. Curr. Pharm. Des., 2005, 11(9), 1091-104.
59. McLaughlin, F.; La Thangue, N. B. Histone deacetylase inhibitors open new doors in cancer therapy. Biochem. Pharmacol., 2004, 68(6), 1139-1144.
60. Clarke, N.; Germain, P.; Altucci, L.; Gronemeyer, H. Retinoids: potential in cancer prevention and therapy. Expert Rev. Mol. Med., 2004, 6(25), 1-23.
61. de Ruijter, A. J.; van Gennip, A. H.; Caron, H. N.; Kemp, S.; van Kuilenburg, A. B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J., 2003, 370(Pt 3), 737-749.
62. Rosato, R. R.; Grant, S. Histone deacetylase inhibitors in cancer therapy. Cancer Biol. Ther., 2003, 2(1), 30-37.
63. Furumai, R.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Yoshida, M.; Horinouchi, S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA, 2001, 98(1), 87-92.
64. Altucci, L.; Gronemeyer, H. The promise of retinoids to fight against cancer. Nat. Rev. Cancer, 2001, 1(3), 181-193.
65. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 1999, 401(6749), 188-193.
66. Brinkmann, H.; Dahler, A. L.; Popa, C.; Serewko, M. M.; Parsons, P. G.; Gabrielli, B. G.; Burgess, A. J.; Saunders, N. A. Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. J. Biol. Chem., 2001, 276(25), 22491-22499.
67. Drobic, B.; Dunn, K. L.; Espino, P. S.; Davie, J. R. Abnormalities of chromatin in tumor cells. Exs, 2006, (96), 25-47.
68. Marks, P. A.; Dokmanovic, M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin. Investig. Drugs, 2005, 14(12), 1497-511.
69. Gayther, S. A.; Batley, S. J.; Linger, L.; Bannister, A.; Thorpe, K.; Chin, S. F.; Daigo, Y.; Russell, P.; Wilson, A.; Sowter, H. M.; Delhanty, J. D.; Ponder, B. A.; Kouzarides, T.; Caldas, C. Mutations truncating the EP300 acetylase in human cancers. Nat. Genet., 2000, 24(3), 300-303.
70. Taddei, A.; Roche, D.; Bickmore, W. A.; Almouzni, G. The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? EMBO Rep., 2005, 6(6), 520-524.
71. Albert, M.; Helin, K. Histone methyltransferases in cancer. Semin. Cell Dev. Biol., 2010, 21(2), 209-220.
72. Bannister, A. J.; Kouzarides, T. Reversing histone methylation. Nature, 2005, 436(7054), 1103-6.
73. Chi, P.; Allis, C. D.; Wang, G. G. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer, 2010, 10(7), 457-469.
74. Peters, A. H.; O'Carroll, D.; Scherthan, H.; Mechtler, K.; Sauer, S.; Schofer, C.; Weipoltshammer, K.; Pagani, M.; Lachner, M.; Kohlmaier, A.; Opravil, S.; Doyle, M.; Sibilia, M.; Jenuwein, T. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell, 2001, 107(3), 323-337.
75. Lin, Y. W.; Chen, H. M.; Fang, J. Y. Gene silencing by the Polycomb group proteins and associations with cancer. Cancer Invest., 2011, 29(3), 187-195.
76. Myzak, M. C.; Dashwood, R. H. Chemoprotection by sulforaphane: keep one eye beyond Keap1. Cancer Lett., 2006, 233(2), 208-218.
77. Fu, S.; Kurzrock, R. Development of curcumin as an epigenetic agent. Cancer, 2010, 116(20), 4670-4676.
78. Myzak, M. C.; Ho, E.; Dashwood, R. H. Dietary agents as histone deacetylase inhibitors. Mol. Carcinog., 2006, 45(6), 443-446.
79. Ho, E.; Beaver, L. M.; Williams, D. E.; Dashwood, R. H. Dietary factors and epigenetic regulation for prostate cancer prevention. Adv. Nutr., 2011, 2(6), 497-510.
80. Dashwood, R. H.; Myzak, M. C.; Ho, E. Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis, 2006, 27(2), 344-349.
81. Dashwood, R. H.; Ho, E. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin. Cancer Biol., 2007, 17(5), 363-369.
82. Pham, T. X.; Lee, J. Dietary regulation of histone acetylases and deacetylases for the prevention of metabolic diseases. Nutrients, 2012, 4(12), 1868-1886.
83. Ho, E.; Clarke, J. D.; Dashwood, R. H. Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention. J. Nutr., 2009, 139(12), 2393-2396.
84. Reuter, S.; Gupta, S. C.; Park, B.; Goel, A.; Aggarwal, B. B. Epigenetic changes induced by curcumin and other natural compounds. Genes Nutr., 2011, 6(2), 93-108.
85. Hardy, T. M.; Tollefsbol, T. O. Epigenetic diet: impact on the epigenome and cancer. Epigenomics, 2011, 3(4), 503-518.
86. Meeran, S. M.; Ahmed, A.; Tollefsbol, T. O. Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin. Epigenetics, 2010, 1(3-4), 101-116.
87. Zhang, Y.; Chen, H. Genistein, an epigenome modifier during cancer prevention. Epigenetics, 2011, 6(7), 888-891.
88. Hede, K. Histone deacetylase inhibitors sit at crossroads of diet, aging, cancer. J. Natl. Cancer Inst., 2006, 98(6), 377-9.
89. Martin, S. L.; Hardy, T. M.; Tollefsbol, T. O. Medicinal chemistry of the epigenetic diet and caloric restriction. Curr. Med. Chem., 2013, 20(32), 4050-4059.
90. Rajendran, P.; Williams, D. E.; Ho, E.; Dashwood, R. H. Metabolism as a key to histone deacetylase inhibition. Crit. Rev. Biochem. Mol. Biol., 2011, 46(3), 181-199.
91. Nian, H.; Delage, B.; Ho, E.; Dashwood, R. H. Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds. Environ. Mol. Mutagen., 2009, 50(3), 213-221.
92. Clarke, J. D.; Dashwood, R. H.; Ho, E. Multi-targeted prevention of cancer by sulforaphane. Cancer Lett., 2008, 269(2), 291-304.
93. Gupta, S. C.; Prasad, S.; Kim, J. H.; Patchva, S.; Webb, L. J.; Priyadarsini, I. K.; Aggarwal, B. B. Multitargeting by curcumin as revealed by molecular interaction studies. Nat. Prod. Rep., 2011, 28(12), 1937-1955.
94. Ong, T. P.; Moreno, F. S.; Ross, S. A. Targeting the epigenome with bioactive food components for cancer prevention. J. Nutrigenet. Nutrigenomics, 2011, 4(5), 275-292.
95. Fimognari, C.; Lenzi, M.; Hrelia, P. Chemoprevention of cancer by isothiocyanates and anthocyanins: mechanisms of action and structure-activity relationship. Curr. Med. Chem., 2008, 15(5), 440-447.
96. Zhang, Y.; Talalay, P.; Cho, C. G.; Posner, G. H. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc. Natl. Acad. Sci. USA, 1992, 89(6), 2399-2403.
97. Fahey, J. W.; Zhang, Y.; Talalay, P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc. Natl. Acad. Sci. USA, 1997, 94(19), 10367-10372.
98. Sasaki, K.; Neyazaki, M.; Shindo, K.; Ogawa, T.; Momose, M. Quantitative profiling of glucosinolates by LC-MS analysis reveals several cultivars of cabbage and kale as promising sources of sulforaphane. J. Chromatogr. B, Anal. Technol. Biomed. Life Sci., 2012, 903, 171-176.
99. Bhamre, S.; Sahoo, D.; Tibshirani, R.; Dill, D. L.; Brooks, J. D. Temporal changes in gene expression induced by sulforaphane in human prostate cancer cells. Prostate, 2009, 69(2), 181-190.
100. Dashwood, R. H.; Ho, E. Dietary agents as histone deacetylase inhibitors: sulforaphane and structurally related isothiocyanates. Nutr. Rev., 2008, 66(Suppl 1), S36-S38.
101. Telang, U.; Brazeau, D. A.; Morris, M. E. Comparison of the effects of phenethyl isothiocyanate and sulforaphane on gene expression in breast cancer and normal mammary epithelial cells. Exp. Biol. Med. (Maywood), 2009, 234(3), 287-295.
102. Bryant, C. S.; Kumar, S.; Chamala, S.; Shah, J.; Pal, J.; Haider, M.; Seward, S.; Qazi, A. M.; Morris, R.; Semaan, A.; Shammas, M. A.; Steffes, C.; Potti, R. B.; Prasad, M.; Weaver, D. W.; Batchu, R. B. Sulforaphane induces cell cycle arrest by protecting RB-E2F-1 complex in epithelial ovarian cancer cells. Mol. Cancer, 2010, 9, 47.
103. Bacon, J. R.; Williamson, G.; Garner, R. C.; Lappin, G.; Langouet, S.; Bao, Y. Sulforaphane and quercetin modulate PhIP-DNA adduct formation in human HepG2 cells and hepatocytes. Carcinogenesis, 2003, 24(12), 1903-1911.
104. Chu, W. F.; Wu, D. M.; Liu, W.; Wu, L. J.; Li, D. Z.; Xu, D. Y.; Wang, X. F. Sulforaphane induces G2-M arrest and apoptosis in high metastasis cell line of salivary gland adenoid cystic carcinoma. Oral Oncol., 2009, 45(11), 998-1004.
105. Dinkova-Kostova, A. T.; Fahey, J. W.; Wade, K. L.; Jenkins, S. N.; Shapiro, T. A.; Fuchs, E. J.; Kerns, M. L.; Talalay, P. Induction of the phase 2 response in mouse and human skin by sulforaphanecontaining broccoli sprout extracts. Cancer Epidemiol. Biomarkers Prev. 2007, 16(4), 847-851.
106. Myzak, M. C.; Karplus, P. A.; Chung, F. L.; Dashwood, R. H. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res., 2004, 64(16), 5767-5774.
107. Rajendran, P.; Kidane, A. I.; Yu, T. W.; Dashwood, W. M.; Bisson, W. H.; Lohr, C. V.; Ho, E.; Williams, D. E.; Dashwood, R. H. HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates. Epigenetics, 2013, 8(6), 612-623.
108. Rajendran, P.; Delage, B.; Dashwood, W. M.; Yu, T. W.; Wuth, B.; Williams, D. E.; Ho, E.; Dashwood, R. H. Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly. Mol. Cancer, 2011, 10, 68.
109. Gibbs, A.; Schwartzman, J.; Deng, V.; Alumkal, J. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc. Natl. Acad. Sci. USA, 2009, 106(39), 16663-16668.
110. Myzak, M. C.; Hardin, K.; Wang, R.; Dashwood, R. H.; Ho, E. Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis, 2006, 27(4), 811-819.
111. Clarke, J. D.; Hsu, A.; Yu, Z.; Dashwood, R. H.; Ho, E. Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells. Mol. Nutr. Food Res., 2011, 55(7), 999-1009.
112. Myzak, M. C.; Tong, P.; Dashwood, W. M.; Dashwood, R. H.; Ho, E. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp. Biol. Med. (Maywood), 2007, 232(2), 227-234.
113. Myzak, M. C.; Dashwood, W. M.; Orner, G. A.; Ho, E.; Dashwood, R. H. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J., 2006, 20(3), 506-568.
114. Pledgie-Tracy, A.; Sobolewski, M. D.; Davidson, N. E. Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol. Cancer Ther., 2007, 6(3), 1013-1021.
115. Balasubramanian, S.; Chew, Y. C.; Eckert, R. L. Sulforaphane suppresses polycomb group protein level via a proteasomedependent mechanism in skin cancer cells. Mol. Pharmacol., 2011, 80(5), 870-878.
116. Singh, S. V.; Herman-Antosiewicz, A.; Singh, A. V.; Lew, K. L.; Srivastava, S. K.; Kamath, R.; Brown, K. D.; Zhang, L.; Baskaran, R. Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C. J. Biol. Chem., 2004, 279(24), 25813-25822.
117. Herman-Antosiewicz, A.; Xiao, H.; Lew, K. L.; Singh, S. V. Induction of p21 protein protects against sulforaphane-induced mitotic arrest in LNCaP human prostate cancer cell line. Mol. Cancer Ther., 2007, 6(5), 1673-1881.
118. Jackson, S. J.; Singletary, K. W. Sulforaphane inhibits human MCF-7 mammary cancer cell mitotic progression and tubulin polymerization. J. Nutr., 2004, 134(9), 2229-2236.
119. Beklemisheva, A. A.; Fang, Y.; Feng, J.; Ma, X.; Dai, W.; Chiao, J. W. Epigenetic mechanism of growth inhibition induced by phenylhexyl isothiocyanate in prostate cancer cells. Anticancer Res., 2006, 26(2A), 1225-1230.
120. Batra, S.; Sahu, R. P.; Kandala, P. K.; Srivastava, S. K. Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells. Mol. Cancer Ther., 2010, 9(6), 1596-1608.
121. Jiang, S.; Ma, X.; Huang, Y.; Xu, Y.; Zheng, R.; Chiao, J. W. Reactivating aberrantly hypermethylated p15 gene in leukemic T cells by a phenylhexyl isothiocyanate mediated inter-active mechanism on DNA and chromatin. J. Hematol. Oncol., 2010, 3, 48.
122. Lu, Q.; Lin, X.; Feng, J.; Zhao, X.; Gallagher, R.; Lee, M. Y.; Chiao, J. W.; Liu, D. Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J. Hematol. Oncol., 2008, 1, 6.
123. Zou, Y.; Ma, X.; Huang, Y.; Hong, L.; Chiao, J. W. Effect of phenylhexyl isothiocyanate on aberrant histone H3 methylation in primary human acute leukemia. J. Hematol. Oncol., 2012, 5, 36.
124. Aggarwal, B. B.; Sung, B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol. Sci., 2009, 30(2), 85-94.
125. Lao, C. D.; Ruffin, M. T. t.; Normolle, D.; Heath, D. D.; Murray, S. I.; Bailey, J. M.; Boggs, M. E.; Crowell, J.; Rock, C. L.; Brenner, D. E. Dose escalation of a curcuminoid formulation. BMC Complement. Altern. Med., 2006, 6, 10.
126. Sharma, R. A.; Gescher, A. J.; Steward, W. P. Curcumin: The story so far. Eur. J. Cancer, 2005, 41(13), 1955-1968.
127. Balasubramanyam, K.; Varier, R. A.; Altaf, M.; Swaminathan, V.; Siddappa, N. B.; Ranga, U.; Kundu, T. K. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem., 2004, 279(49), 51163-51171.
128. Maheshwari, R. K.; Singh, A. K.; Gaddipati, J.; Srimal, R. C. Multiple biological activities of curcumin: A short review. Life Sci., 2006, 78(18), 2081-2087.
129. Goel, A.; Aggarwal, B. B. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr. Cancer, 2010, 62(7), 919-930.
130. Lee, S. J.; Krauthauser, C.; Maduskuie, V.; Fawcett, P. T.; Olson, J. M.; Rajasekaran, S. A. Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo. BMC cancer, 2011, 11, 144.
131. Collins, H. M.; Abdelghany, M. K.; Messmer, M.; Yue, B.; Deeves, S. E.; Kindle, K. B.; Mantelingu, K.; Aslam, A.; Winkler, G. S.; Kundu, T. K.; Heery, D. M. Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells. BMC Cancer, 2013, 13, 37.
132. Roy, M.; Mukherjee, S. Reversal of resistance towards cisplatin by curcumin in cervical cancer cells. Asian Pac. J. Cancer Prev., 2014, 15(3), 1403-1410.
133. Shah, S.; Prasad, S.; Knudsen, K. E. Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression. Cancer Res., 2012, 72(5), 1248-1259.
134. Shu, L.; Khor, T. O.; Lee, J. H.; Boyanapalli, S. S.; Huang, Y.; Wu, T. Y.; Saw, C. L.; Cheung, K. L.; Kong, A. N. Epigenetic CpG demethylation of the promoter and reactivation of the expression of Neurog1 by curcumin in prostate LNCaP cells. AAPS J., 2011, 13(4), 606-614.
135. Graham, H. N. Green tea composition, consumption, and polyphenol chemistry. Prev. Med., 1992, 21(3), 334-350.
136. Lambert, J. D.; Yang, C. S. Mechanisms of cancer prevention by tea constituents. J. Nutr., 2003, 133(10), 3262S-3267S.
137. Lin, J. K.; Liang, Y. C.; Lin-Shiau, S. Y. Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade. Biochem. Pharmacol., 1999, 58(6), 911-915.
138. Fang, M.; Chen, D.; Yang, C. S. Dietary polyphenols may affect DNA methylation. J. Nutr., 2007, 137(1 Suppl), 223S-228S.
139. Lee, W. J.; Shim, J. Y.; Zhu, B. T. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol. Pharmacol., 2005, 68(4), 1018-1030.
140. Meeran, S. M.; Patel, S. N.; Chan, T. H.; Tollefsbol, T. O. A novel prodrug of epigallocatechin-3-gallate: differential epigenetic hTERT repression in human breast cancer cells. Cancer Prev. Res. (Phila), 2011, 4(8), 1243-1254.
141. Thakur, V. S.; Gupta, K.; Gupta, S. Green tea polyphenols increase p53 transcriptional activity and acetylation by suppressing class I histone deacetylases. Int. J. Oncol., 2012, 41(1), 353-361.
142. Li, Y.; Yuan, Y. Y.; Meeran, S. M.; Tollefsbol, T. O. Synergistic epigenetic reactivation of estrogen receptor-alpha (ERalpha) by combined green tea polyphenol and histone deacetylase inhibitor in ERalpha-negative breast cancer cells. Mol. Cancer, 2010, 9, 274.
143. Choudhury, S. R.; Balasubramanian, S.; Chew, Y. C.; Han, B.; Marquez, V. E.; Eckert, R. L. (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. Carcinogenesis, 2011, 32(10), 1525-1532.
144. Nandakumar, V.; Vaid, M.; Katiyar, S. K. (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. Carcinogenesis, 2011, 32(4), 537-544.
145. Balasubramanian, S.; Adhikary, G.; Eckert, R. L. The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallatedependent suppression of skin cancer cell survival. Carcinogenesis, 2010, 31(3), 496-503.
146. Li, G. X.; Chen, Y. K.; Hou, Z.; Xiao, H.; Jin, H.; Lu, G.; Lee, M. J.; Liu, B.; Guan, F.; Yang, Z.; Yu, A.; Yang, C. S. Pro-oxidative activities and dose-response relationship of (-)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: A comparative study in vivo and in vitro. Carcinogenesis, 2010, 31(5), 902-910.
147. Kaufman, P. B.; Duke, J. A.; Brielmann, H.; Boik, J.; Hoyt, J. E. A comparative survey of leguminous plants as sources of the isoflavones, genistein and daidzein: implications for human nutrition and health. J. Altern. Complement. Med., 1997, 3(1), 7-12.
148. Wang, B. S.; Juang, L. J.; Yang, J. J.; Chen, L. Y.; Tai, H. M.; Huang, M. H. Antioxidant and Antityrosinase Activity of Flemingia macrophylla and Glycine tomentella Roots. Evid. Based Complement. Alternat. Med., 2012, 2012, 431081.
149. Alves, R. C.; Almeida, I. M.; Casal, S.; Oliveira, M. B. Isoflavones in coffee: influence of species, roast degree, and brewing method. J. Agric. Food Chem., 2010, 58(5), 3002-3007.
150. Li, Y.; Tollefsbol, T. O. Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr. Med. Chem., 2010, 17(20), 2141-2151.
151. Li, Y.; Liu, L.; Andrews, L. G.; Tollefsbol, T. O. Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms. Int. J. Cancer, 2009, 125(2), 286-296.
152. Kuiper, G. G.; Lemmen, J. G.; Carlsson, B.; Corton, J. C.; Safe, S. H.; van der Saag, P. T.; van der Burg, B.; Gustafsson, J. A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology, 1998, 139(10), 4252-4263.
153. Barnes, S. Effect of genistein on in vitro and in vivo models of cancer. J. Nutr., 1995, 125(3 Suppl), 777S-783S.
154. Su, S. J.; Yeh, T. M.; Chuang, W. J.; Ho, C. L.; Chang, K. L.; Cheng, H. L.; Liu, H. S.; Cheng, H. L.; Hsu, P. Y.; Chow, N. H. The novel targets for anti-angiogenesis of genistein on human cancer cells. Biochem. Pharmacol., 2005, 69(2), 307-318.
155. Li, Y.; Chen, H.; Hardy, T. M.; Tollefsbol, T. O. Epigenetic regulation of multiple tumor-related genes leads to suppression of breast tumorigenesis by dietary genistein. PLoS One, 2013, 8(1), e54369.
156. Basak, S.; Pookot, D.; Noonan, E. J.; Dahiya, R. Genistein downregulates androgen receptor by modulating HDAC6-Hsp90 chaperone function. Mol. Cancer Ther., 2008, 7(10), 3195-3202.
157. Majid, S.; Dar, A. A.; Shahryari, V.; Hirata, H.; Ahmad, A.; Saini, S.; Tanaka, Y.; Dahiya, A. V.; Dahiya, R. Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancer. Cancer, 2010, 116(1), 66-76.
158. Majid, S.; Dar, A. A.; Ahmad, A. E.; Hirata, H.; Kawakami, K.; Shahryari, V.; Saini, S.; Tanaka, Y.; Dahiya, A. V.; Khatri, G.; Dahiya, R. BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis, 2009, 30(4), 662-670.
159. Wang, H.; Li, Q.; Chen, H. Genistein affects histone modifications on Dickkopf-related protein 1 (DKK1) gene in SW480 human colon cancer cell line. PLoS One, 2012, 7(7), e40955.
160. Groh, I. A.; Chen, C.; Luske, C.; Cartus, A. T.; Esselen, M. Plant polyphenols and oxidative metabolites of the herbal alkenylbenzene methyleugenol suppress histone deacetylase activity in human colon carcinoma cells. J. Nutr. Metab., 2013, 2013, 821082.
161. Pong, R. C.; Roark, R.; Ou, J. Y.; Fan, J.; Stanfield, J.; Frenkel, E.; Sagalowsky, A.; Hsieh, J. T. Mechanism of increased coxsackie and adenovirus receptor gene expression and adenovirus uptake by phytoestrogen and histone deacetylase inhibitor in human bladder cancer cells and the potential clinical application. Cancer Res., 2006, 66(17), 8822-8828.
162. Baur, J. A.; Sinclair, D. A. Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov., 2006, 5(6), 493-506.
163. Gu, X.; Creasy, L.; Kester, A.; Zeece, M. Capillary electrophoretic determination of resveratrol in wines. J. Agric. Food Chem., 1999, 47(8), 3223-3227.
164. Li, G.; Rivas, P.; Bedolla, R.; Thapa, D.; Reddick, R. L.; Ghosh, R.; Kumar, A. P. Dietary resveratrol prevents development of highgrade prostatic intraepithelial neoplastic lesions: involvement of SIRT1/S6K axis. Cancer Prev. Res. (Phila), 2013, 6(1), 27-39.
165. Bourguignon, L. Y.; Xia, W.; Wong, G. Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells. J. Biol. Chem., 2009, 284(5), 2657-2671.
166. Wang, R. H.; Sengupta, K.; Li, C.; Kim, H. S.; Cao, L.; Xiao, C.; Kim, S.; Xu, X.; Zheng, Y.; Chilton, B.; Jia, R.; Zheng, Z. M.; Appella, E.; Wang, X. W.; Ried, T.; Deng, C. X. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell, 2008, 14(4), 312-323.
167. Scuto, A.; Kirschbaum, M.; Buettner, R.; Kujawski, M.; Cermak, J. M.; Atadja, P.; Jove, R. SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-kappaB/STAT3 complex to its promoter in malignant lymphoid cells. Cell Death Dis., 2013, 4, e635.
168. Venturelli, S.; Berger, A.; Bocker, A.; Busch, C.; Weiland, T.; Noor, S.; Leischner, C.; Schleicher, S.; Mayer, M.; Weiss, T. S.; Bischoff, S. C.; Lauer, U. M.; Bitzer, M. Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells. PLoS One, 2013, 8(8), e73097.
169. Kim, J. E.; Kim, H. S.; Shin, Y. J.; Lee, C. S.; Won, C.; Lee, S. A.; Lee, J. W.; Kim, Y.; Kang, J. S.; Ye, S. K.; Chung, M. H. LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression. Exp. Mol. Med., 2008, 40(5), 514-522.
170. Abdulla, A.; Zhao, X.; Yang, F. Natural Polyphenols Inhibit Lysine-Specific Demethylase-1. J. Biochem. Pharmacol. Res., 2013, 1(1), 56-63.
171. Podhorecka, M.; Halicka, D.; Klimek, P.; Kowal, M.; Chocholska, S.; Dmoszynska, A. Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia. Ann. Hematol., 2011, 90(2), 173-83.
172. Hong, Y. B.; Kang, H. J.; Kim, H. J.; Rosen, E. M.; Dakshanamurthy, S.; Rondanin, R.; Baruchello, R.; Grisolia, G.; Daniele, S.; Bae, I. Inhibition of cell proliferation by a resveratrol analog in human pancreatic and breast cancer cells. Exp. Mol. Med., 2009, 41(3), 151-60.
173. Lemire, M.; Fillion, M.; Barbosa, F., Jr.; Guimaraes, J. R.; Mergler, D. Elevated levels of selenium in the typical diet of Amazonian riverside populations. Sci. Total Environ., 2010, 408(19), 4076-4084.
174. Hu, Y.; McIntosh, G. H.; Le Leu, R. K.; Nyskohus, L. S.; Woodman, R. J.; Young, G. P. Combination of selenium and green tea improves the efficacy of chemoprevention in a rat colorectal cancer model by modulating genetic and epigenetic biomarkers. PLoS One, 2013, 8(5), e64362.
175. Xiang, N.; Zhao, R.; Song, G.; Zhong, W. Selenite reactivates silenced genes by modifying DNA methylation and histones in prostate cancer cells. Carcinogenesis, 2008, 29(11), 2175-2181.
176. Desai, D.; Salli, U.; Vrana, K. E.; Amin, S. SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(6), 2044-2047.
177. Karelia, N.; Desai, D.; Hengst, J. A.; Amin, S.; Rudrabhatla, S. V.; Yun, J. Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells. Bioorg. Med. Chem. Lett., 2010, 20(22), 6816-6819.
178. Goulet, A. C.; Watts, G.; Lord, J. L.; Nelson, M. A. Profiling of selenomethionine responsive genes in colon cancer by microarray analysis. Cancer Biol. Ther., 2007, 6(4), 494-503.
179. Xiao, X.; Shi, D.; Liu, L.; Wang, J.; Xie, X.; Kang, T.; Deng, W. Quercetin suppresses cyclooxygenase-2 expression and angiogenesis through inactivation of P300 signaling. PLoS One, 2011, 6(8), e22934.
180. Druesne, N.; Pagniez, A.; Mayeur, C.; Thomas, M.; Cherbuy, C.; Duee, P. H.; Martel, P.; Chaumontet, C. Diallyl disulfide (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines. Carcinogenesis, 2004, 25(7), 1227-1236.
181. Zhao, J.; Huang, W. G.; He, J.; Tan, H.; Liao, Q. J.; Su, Q. Diallyl disulfide suppresses growth of HL-60 cell through increasing histone acetylation and p21WAF1 expression in vivo and in vitro. Acta Pharmacol. Sin., 2006, 27(11), 1459-1466.
182. Rogan, E. G. The natural chemopreventive compound indole-3-carbinol: state of the science. In vivo, 2006, 20(2), 221-228.
183. Kim, Y. S.; Milner, J. A. Targets for indole-3-carbinol in cancer prevention. J. Nutr. Biochem., 2005, 16(2), 65-73.
184. Beaver, L. M.; Yu, T. W.; Sokolowski, E. I.; Williams, D. E.; Dashwood, R. H.; Ho, E. 3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells. Toxicol. Appl. Pharmacol., 2012, 263(3), 345-351.
185. Li, Y.; Li, X.; Guo, B. Chemopreventive agent 3,3'-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases. Cancer Res., 2010, 70(2), 646-654.
186. Balasubramanyam, K.; Altaf, M.; Varier, R. A.; Swaminathan, V.; Ravindran, A.; Sadhale, P. P.; Kundu, T. K. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J. Biol. Chem., 2004, 279(32), 33716-33726.
187. Kamimura, A.; Takahashi, T. Procyanidin B-3, isolated from barley and identified as a hair-growth stimulant, has the potential to counteract inhibitory regulation by TGF-beta1. Exp. Dermatol., 2002, 11(6), 532-541.
188. Quinde-Axtell, Z.; Baik, B. K. Phenolic compounds of barley grain and their implication in food product discoloration. J. Agric. Food Chem., 2006, 54(26), 9978-9784.
189. Benavides, A.; Montoro, P.; Bassarello, C.; Piacente, S.; Pizza, C. Catechin derivatives in Jatropha macrantha stems: characterisation and LC/ESI/MS/MS quali-quantitative analysis. J. Pharm. Biomed. Anal., 2006, 40(3), 639-647.
190. Choi, K. C.; Park, S.; Lim, B. J.; Seong, A. R.; Lee, Y. H.; Shiota, M.; Yokomizo, A.; Naito, S.; Na, Y.; Yoon, H. G. Procyanidin B3, an inhibitor of histone acetyltransferase, enhances the action of antagonist for prostate cancer cells via inhibition of p300-dependent acetylation of androgen receptor. Biochem. J., 2011, 433 (1), 235-244.
191. Lubas, W. A.; Frank, D. W.; Krause, M.; Hanover, J. A. O-Linked GlcNAc transferase is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats. J. Biol. Chem., 1997, 272(14), 9316-9324.
192. Fujiki, R.; Hashiba, W.; Sekine, H.; Yokoyama, A.; Chikanishi, T.; Ito, S.; Imai, Y.; Kim, J.; He, H. H.; Igarashi, K.; Kanno, J.; Ohtake, F.; Kitagawa, H.; Roeder, R. G.; Brown, M.; Kato, S. GlcNAcylation of histone H2B facilitates its monoubiquitination. Nature, 2011, 480(7378), 557-560.
193. Shapiro, T. A.; Fahey, J. W.; Dinkova-Kostova, A. T.; Holtzclaw, W. D.; Stephenson, K. K.; Wade, K. L.; Ye, L.; Talalay, P. Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: A clinical phase I study. Nutr. Cancer, 2006, 55(1), 53-62.
194. Kensler, T. W.; Chen, J. G.; Egner, P. A.; Fahey, J. W.; Jacobson, L. P.; Stephenson, K. K.; Ye, L.; Coady, J. L.; Wang, J. B.; Wu, Y.; Sun, Y.; Zhang, Q. N.; Zhang, B. C.; Zhu, Y. R.; Qian, G. S.; Carmella, S. G.; Hecht, S. S.; Benning, L.; Gange, S. J.; Groopman, J. D.; Talalay, P. Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. Cancer Epidemiol. Biomarkers Prev., 2005, 14(11 Pt 1), 2605-2613.